1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,870 | 0,960 | 08:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.03. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.03. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 19.12.24 | LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance | 162 | PR Newswire | Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY
Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY
Gross margin... ► Artikel lesen | |
| 13.12.24 | LakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China | 191 | GlobeNewswire (Europe) | BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a leading global biopharmaceutical company focused on the innovation... ► Artikel lesen | |
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 25.10.24 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine | 554 | PR Newswire | GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical... ► Artikel lesen | |
| 10.10.24 | XFRA H6Z0: WIEDERAUFNAHME/RESUMPTION | 251 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 08.10.24 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance | 208 | PR Newswire | GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering... ► Artikel lesen | |
| 04.10.24 | XFRA H6Z0: AUSSETZUNG/SUSPENSION | 382 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLAKESHORE BIOP.... ► Artikel lesen | |
| 04.10.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 04.10.2024 | 452 | Xetra Newsboard | The following instruments on XETRA do have their first trading 04.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 04.10.2024
Aktien
1 US59564R8079 Biodexa Pharmaceuticals... ► Artikel lesen | |
| 03.10.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.10.2024 | 587 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.10.2024ISIN NameUS59564R7089 BIODEXA... ► Artikel lesen | |
| 03.10.24 | XFRA ISIN CHANGE | 749 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA3874371147 Granite REIT LP 03.10.2024 CA3874372053 Granite REIT LP 04.10.2024 Tausch 1:1US86323X1063 Streamline... ► Artikel lesen | |
| 01.10.24 | XFRA H6Z: AUSSETZUNG/SUSPENSION | 315 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLAKESHORE BIOP.DL-... ► Artikel lesen | |
| 27.09.24 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation | 285 | PR Newswire | GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering... ► Artikel lesen | |
| 15.08.24 | LakeShore Biopharma Co., Ltd: LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 | 665 | PR Newswire | Gross margin increased to 79.5%; product pipeline continues to advance
Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025
GAITHERSBURG,... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,885 | -0,28 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 47,005 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| VERA THERAPEUTICS | 23,560 | +4,34 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| ARTELO BIOSCIENCES | 13,180 | 0,00 % | Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain | First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30... ► Artikel lesen | |
| EVOTEC | 7,204 | +0,92 % | Evotec macht Hoffnung: Durchbruch bei Nierentherapie? | Evotec kooperiert mit dem Forschungsnetzwerk NURTuRE-AKI, um neue Therapien gegen akutes Nierenversagen (AKI) zu entwickeln - ein bislang kaum behandelbares Krankheitsfeld mit hoher Sterblichkeitsrate.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 42,050 | -2,21 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 18,190 | 0,00 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| NURIX THERAPEUTICS | 11,390 | -2,15 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,050 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| TANGO THERAPEUTICS | 5,120 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ... | BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 43,490 | +0,25 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
| MODERNA | 23,810 | +2,17 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
| CELCUITY | 13,350 | 0,00 % | Celcuity Inc.: Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib | • In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"),the six-month radiographic progression... ► Artikel lesen | |
| VOR BIOPHARMA | 1,610 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,250 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen |
Das Unternehmen LAKESHORE BIOPHARMA CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,735 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.